JPRN-jRCT2080225027已完成Unknown
A compassionate use study of satralizumab in neuromyelitis optica spectrum disorders.(NMOSD) patients
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
o new safety concern of satralizumab in NMOSD patients was observed from the study.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients diagnosed as having either:
- •- NMO as defined by 2006 criteria
- •- NMOSD as defined by either of the following Wingerchuk 2007 criteria with anti aquaporin 4 antibody (AQP4Ab) seropositive status at screening
- •- NMOSD as defined by 2015 criteria
排除标准
- •(1) Patients who have history of Alemtuzumab, total body irradiation, or marrow transplant
- •(2) Any previous treatment with anti-cluster of differentiation (CD) 20, eculizumab, belimumab, interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate within 6 months prior to baseline
- •(3) Any previous treatment with anti-CD4, cladribine or mitoxantrone within 2 years prior to baseline.
- •(4) Treatment with any investigational agent within 3 months prior to baseline.
研究者
相似试验
撤回
早期 1 期
Satralizumab in Aneurysmal Subarachnoid HemorrhageAneurysmal Subarachnoid HemorrhageDelayed Cerebral IschemiaNCT05727657University of Florida
进行中（未招募）
3 期
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisNCT05503264Hoffmann-La Roche122
招募中
1 期
Clinical pharmacology study of satralizumab in patients with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD)euromyelitis optica spectrum disorders(NMOSD)JPRN-jRCT2051230006Okuno Tatsusada3
尚未招募
2 期
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum DisordersNeuromyelitis Optica Spectrum DisorderNCT04064944Third Affiliated Hospital, Sun Yat-Sen University144
已完成
2 期
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic SclerosisSystemic SclerosisNCT05214794Maruho Co., Ltd.6